Sign In
Buy DTIL
$6.04
-0.280 (-4.43%)
At Close: Jun 03, 2026
Precision BioSciences Announces Executive Leadership Change
12:00am, Monday, 14'th Dec 2020
DURHAM, N.C., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® gen
Acceptable Toler ability and Safety Profile in 27 Patients with No Graft versus Host Disease (GvHD), No Grade ≥ 3 Cytokine Release Syndrome (CRS) , and No Grade ≥ 3 Neurotoxicity (ICANS)
Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement
07:00am, Friday, 20'th Nov 2020
INDIANAPOLIS, and DURHAM, N.C., Nov. 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and exclusive li
Precision BioSciences: Q3 Earnings Insights
07:28am, Tuesday, 10'th Nov 2020
Shares of Precision BioSciences (NASDAQ:DTIL) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were down 21.95% year over year to ($0.50), which beat the
Precision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business Update
07:00am, Tuesday, 10'th Nov 2020
Expanded allogeneic CAR T development collaboration with Servier to include four new programs targeting hematological and solid tumors
Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020
07:00am, Tuesday, 03'rd Nov 2020
DURHAM, N.C., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® ge
Global Liquid Biopsy Market Analysis and Forecast, 2020-2030 & Implications of COVID-19 Pandemic on the Market - ResearchAndMarkets.com
12:00am, Wednesday, 14'th Oct 2020
The
Arcus Biosciences Announces New Employment Inducement Grants
12:00am, Thursday, 08'th Oct 2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced t
Gilead's Cancer Follies (NASDAQ:GILD)
05:53am, Friday, 02'nd Oct 2020
Gilead's cancer therapy acquisitions record in past years has been troubling. The company's Kite acquisition has exciting therapeutic achievements; the financial contributions are uncertain.
Jennifer Jarrett Returns to Arcus Biosciences as Chief Operating Officer | | IT Business Net
12:07am, Friday, 02'nd Oct 2020
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Jennifer Jar
Systems Oncology, an AI-based Cancer Therapy Discovery and Development Company, Is Honored With a 2020 AZBio Fast Lane Award
12:00am, Wednesday, 23'rd Sep 2020
Systems Oncology is using AI to Innovate Drug Discovery & Development and is being honored with a 2020 AZBio Fast Lane Award for their achievements.
Qihan Biotech Publishes First Clinical Xenotransplantation Prototype, ‘Pig 3.0’, in Nature Biomedical Engineering
12:00am, Monday, 21'st Sep 2020
Qihan Biotech published research reporting the successful production of its first clinical xenotransplantation prototype.
DURHAM, Caroline du Nord, et PARIS, 17 sept. 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq : DTIL), une société biotechnologique en phase...
Arcus Biosciences Announces New Employment Inducement Grants
12:00am, Thursday, 10'th Sep 2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced t
Arcus Biosciences to Participate in Upcoming September 2020 Investor Conferences
12:00am, Thursday, 27'th Aug 2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced t
